Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsRichard Chen, PA
Clinical InstructorAbout
Research
Publications
2026
Mutational patterns in a large cohort of parathyroid carcinomas
Pandya C, Uzilov A, Costa-Guda J, Bellizzi J, Taik P, Moe A, Strahl M, van der Tuin K, Stevenson M, Cavaco B, Cetani F, Marcocci C, Karhu A, Arola J, Schalin-Jäntti C, Morreau H, Thakker R, Schadt E, Sebra R, Li S, Chen R, Arnold A. Mutational patterns in a large cohort of parathyroid carcinomas. Journal Of Endocrinological Investigation 2026, 1-11. PMID: 41879893, DOI: 10.1007/s40618-026-02855-x.Peer-Reviewed Original ResearchParathyroid carcinomaCDC73 mutationsEvaluating patientsSporadic parathyroid carcinomaGermline pathogenic variantsGenotype-phenotype correlationCDC73 geneRecurrent/metastatic diseaseRare malignancyCarcinoma cohortNext-generation DNA sequencingWHO criteriaTargeted therapyClinical featuresTumor typesOncogenic driversPathogenic variantsCarcinomaDriver mutationsPatientsMutation patternsPI3K/mTOR activationIndividualized treatmentCohortPI3K/AKT/mTOR pathwayMonitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients
Nixon A, Navarro F, Zhou K, Abbott C, McDaniel L, Ravi N, Howard L, Brady J, Liu Y, Jia J, Niedzwiecki D, Strickler J, Boyle S, Chen R, Uronis H. Monitoring treatment response using an ultra-sensitive ctDNA assay in advanced esophagogastric cancer patients. Scientific Reports 2026 PMID: 41872254, DOI: 10.1038/s41598-026-43178-4.Peer-Reviewed Original ResearchMetastatic esophagogastric cancerProgression-free survivalOverall survivalTreatment responseAssociated with worse OSAssociated with worse overall survivalDetection of disease progressionPrediction of treatment responsePhase II trialLiquid biopsy approachMonitoring Treatment ResponseEsophagogastric cancer patientsMedian lead timeLiquid biopsy platformTreatment decision-makingCtDNA dynamicsCtDNA assaysCtDNA levelsII trialTumor sizeBiopsy approachTumor DNAEsophagogastric cancerBiopsy platformTumor samplesThe Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
Hunter N, Parsons H, Cope L, Canzoniero J, Navarro F, El-Refai S, Anampa J, Sparano J, Rimawi M, Storniolo A, Mainor C, Nanda R, DeMichele A, Gupta G, Stringer-Reasor E, Lynce F, Cobain E, Puhalla S, Jankowitz R, Rexer B, Mayer I, Hwang E, Blackwell K, El Ayass W, Lee Y, Tweed C, Wilkinson M, Pennisi A, Sun B, Wright P, Gralow J, Chen R, Boyle S, Stearns V, Wolff A, Park B. The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. Journal Of Clinical Oncology 2026, jco2502934. PMID: 41805422, DOI: 10.1200/jco-25-02934.Peer-Reviewed Original ResearchInvasive disease-free survivalTriple-negative breast cancerPathological complete responseCirculating tumor DNAMinimal residual diseaseDetect circulating tumor DNAPathological response evaluationNon-pCR patientsNeoadjuvant therapyNegative predictive valueTumor DNANon-pCRCtDNA-negativeResidual diseaseBreast cancerHuman epidermal growth factor receptor 2 (HER2)-positiveTNBC cohortHER2-positive breast cancerBiomarkers of treatment responseResponse evaluationTherapeutic de-escalationSecondary objectivesDisease-free survivalSuperior risk stratificationLong-term survivalUltrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer
Nishizaki D, Law A, Li B, Abbott C, Chen Y, Lee S, Pyke R, Keough K, Daniels G, Yeung K, Boyle S, Chen R, Kato S. Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer. Npj Precision Oncology 2026, 10: 79. PMID: 41580469, PMCID: PMC12936199, DOI: 10.1038/s41698-026-01287-3.Peer-Reviewed Original ResearchProgression-free survivalMolecular complete responseImmune checkpoint inhibitorsCtDNA monitoringPrognostic of progression-free survivalPredictor of immunotherapy responseLongitudinal plasma samplesEarly molecular responseBaseline to first follow-upCtDNA clearanceFirst follow-upCheckpoint inhibitorsComplete responseCtDNA assaysICI responseOverall survivalImmunotherapy responseResponse assessmentAdvanced/metastatic cancerClinical decision-makingFollow-upSomatic mutationsAdvanced cancerPlasma samplesPatients
2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy
Garralda E, Abbott C, Calahorro A, Mirallas O, Pugh J, Moreno-Cárdenas A, Keough K, Galvao V, Alonso G, Olano A, Villar M, Oberoi A, Bardaji J, Hernando-Calvo A, Braña I, Pretelli G, Ortega B, Arenillas C, Czerniak N, Navarro F, Li B, Pyke R, Ravi N, Zatse C, Grussu F, Sanz M, Viaplana C, Raskina K, Jimenez J, Fasani R, Casbas-Hernandez P, Oflazoglu E, Hodgson D, Reis-Filho J, Felip E, Élez E, Muñoz E, Dienstmann R, Tabernero J, Lopez-Perez R, Nuciforo P, Chen R, Boyle S, Toledo R. Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy. Clinical Cancer Research 2025, 32: 333-349. PMID: 41400436, PMCID: PMC12809116, DOI: 10.1158/1078-0432.ccr-25-2312.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCheckpoint inhibitorsCtDNA dynamicsProgression-FreeOverall survivalCancer treated with immunotherapyTumor-specific mutationsCohort of patientsProspective validation cohortImmune cell engagementBiomarker potentialCtDNA clearanceImmunotherapy modalitiesRadiological responseProlonged survivalCtDNA detectionTreatment initiationTrue progressionRetrospective cohortValidation cohortCell engagementImmunotherapyBispecific antibodiesCancer typesPatientsLongitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction
Black J, Karasaki T, Abbott C, Li B, Veeriah S, Al Bakir M, Liu K, Huebner A, Martínez-Ruiz C, Pawlik P, Moore D, Marinelli D, Shutkever O, Murphy C, Liu L, Grieco C, Grimes K, Navarro F, Pyke R, Bartha G, Keough K, Dea S, Ravi N, Lyle J, Harris J, Brown K, Blackhall F, Hassani F, Fennell D, McGranahan N, Shaw J, Abbosh C, Consortium T, Hackshaw A, Jamal-Hanjani M, Frankell A, Boyle S, Chen R, Swanton C. Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction. Cell 2025, 188: 7083-7098.e18. PMID: 41205598, DOI: 10.1016/j.cell.2025.10.020.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCirculating tumor DNACtDNA detectionEarly stage NSCLCStage non-small cell lung cancerCtDNA kineticsPattern of relapseIntermediate risk groupCell lung cancerLung cancer risk predictionAnatomical patternsCancer risk predictionCtDNA monitoringCtDNA statusAdjuvant therapyTumor DNAPrognostic assessmentLung cancerDisease stratificationRisk groupsTherapeutic strategiesTreatment recommendationsClinical utilityPlasma samplesPatient outcomesClinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Galsky M, Autio K, Cabanski C, Wentzel K, Graff J, Friedlander T, Howes T, Shotts K, Densmore J, Spasic M, Da Silva D, Chen R, Lata J, Skolnik J, Keler T, Yellin M, LaVallee T, Fairchild J, Boffo S, O’Donnell-Tormey J, Dugan U, Bhardwaj N, Subudhi S, Fong L. Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research 2025, 31: 1463-1475. PMID: 39964352, PMCID: PMC11995007, DOI: 10.1158/1078-0432.ccr-24-3693.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerPoly-ICLCAdverse eventsGrade 3 to 4 treatment-related adverse eventsAssociated with clinical benefitAssociated with disease controlResponse rateDisease control rateProgression-free survivalImmune checkpoint therapyComposite response rateCycles 1 to 3Disease controlCDX-301Combination immunotherapyCombined radiotherapyCheckpoint therapyImmunotherapy efficacyOverall survivalOpen-labelPrimary endpointSecondary endpointsCohort BWhole genome sequencing-powered ctDNA sequencing for breast cancer detection
Garcia-Murillas I, Abbott C, Cutts R, Boyle S, Pugh J, Keough K, Li B, Pyke R, Navarro F, Chen R, Dunne K, Bunce C, Johnston S, Ring A, Russell S, Evans A, Skene A, Smith I, Turner N. Whole genome sequencing-powered ctDNA sequencing for breast cancer detection. Annals Of Oncology 2025, 36: 673-681. PMID: 39914664, DOI: 10.1016/j.annonc.2025.01.021.Peer-Reviewed Original ResearchConceptsMolecular residual diseaseClinical relapseHigh riskCtDNA detectionDetection of molecular residual diseaseFollow-upAssociated with relapse-free survivalHigh risk of relapseMedian levelRelapse-free survivalBreast cancer relapseCirculating tumor DNARisk of relapseAssociated with higher riskBreast cancer patientsMedian lead timeLevels of ctDNADetection of ctDNANeoadjuvant therapyResidual diseaseNeoadjuvant chemotherapyOverall survivalPlasma DNATumor DNACancer relapseUltrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Black J, Bartha G, Abbott C, Boyle S, Karasaki T, Li B, Chen R, Harris J, Veeriah S, Colopi M, Bakir M, Liu W, Lyle J, Navarro F, Northcott J, Pyke R, Hill M, Thol K, Huebner A, Bailey C, Colliver E, Martínez-Ruiz C, Grigoriadis K, Pawlik P, Moore D, Marinelli D, Shutkever O, Murphy C, Sivakumar M, Shaw J, Hackshaw A, McGranahan N, Jamal-Hanjani M, Frankell A, Chen R, Swanton C. Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Nature Medicine 2025, 31: 70-76. PMID: 39806071, PMCID: PMC11750713, DOI: 10.1038/s41591-024-03216-y.Peer-Reviewed Original ResearchConceptsCirculating tumor DNAEarly-stage lung adenocarcinomaLung adenocarcinomaPathological TNMCtDNA detectionDisease stratificationEarly-stage lung cancerStage I diseaseEarly-stage tumorsCtDNA levelsI diseaseOverall survivalTumor DNAClinical outcomesPre-operativelyProspective studyLung cancerClinical utilityClinical riskPatientsClinical applicationAdenocarcinomaTRACERx study
2024
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
Tsimberidou A, Alayli F, Okrah K, Drakaki A, Khalil D, Kummar S, Khan S, Hodi F, Oh D, Cabanski C, Gautam S, Meier S, Amouzgar M, Pfeiffer S, Kageyama R, Yang E, Spasic M, Tetzlaff M, Foo W, Hollmann T, Li Y, Adamow M, Wong P, Moore J, Velichko S, Chen R, Kumar D, Bucktrout S, Ibrahim R, Dugan U, Salvador L, Hubbard-Lucey V, O’Donnell-Tormey J, Santulli-Marotto S, Butterfield L, Da Silva D, Fairchild J, LaVallee T, Padrón L, Sharma P. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. Journal Of Experimental Medicine 2024, 221: e20240152. PMID: 39190534, PMCID: PMC11349049, DOI: 10.1084/jem.20240152.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsT cellsImmunological signaturesResponse to ICIResponse to immune checkpoint inhibitorsICI responseDisease control rateAdvanced solid tumorsCD8 T cellsCD4 T cellsAdvanced metastatic cancerNivolumab monotherapyAnti-CTLA4Checkpoint inhibitorsMetastatic diseaseCD8 levelsCD8 percentagesImmunological featuresSolid tumorsMetastatic cancerB cellsControl rateClinical trialsNivolumabCD8